BNP PARIBAS ASSET MANAGEMENT Holding S.A. Grows Stock Holdings in Humana Inc. (NYSE:HUM)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Humana Inc. (NYSE:HUM) by 356.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 87,939 shares of the insurance provider’s stock after buying an additional 68,655 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.07% of Humana worth $30,490,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Entropy Technologies LP raised its position in shares of Humana by 80.5% in the 1st quarter. Entropy Technologies LP now owns 18,133 shares of the insurance provider’s stock valued at $6,287,000 after purchasing an additional 8,087 shares during the last quarter. Heritage Wealth Advisors raised its position in shares of Humana by 25.6% in the 1st quarter. Heritage Wealth Advisors now owns 255 shares of the insurance provider’s stock valued at $88,000 after purchasing an additional 52 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Humana by 3.4% in the 1st quarter. ProShare Advisors LLC now owns 19,962 shares of the insurance provider’s stock valued at $6,921,000 after purchasing an additional 658 shares during the last quarter. Cognios Beta Neutral Large Cap Fund LP raised its position in shares of Humana by 14.6% in the 1st quarter. Cognios Beta Neutral Large Cap Fund LP now owns 1,656 shares of the insurance provider’s stock valued at $574,000 after purchasing an additional 211 shares during the last quarter. Finally, Avantax Advisory Services Inc. raised its position in shares of Humana by 11.2% in the 1st quarter. Avantax Advisory Services Inc. now owns 2,721 shares of the insurance provider’s stock valued at $943,000 after purchasing an additional 275 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

HUM traded down $6.91 on Friday, hitting $381.98. 210,093 shares of the company’s stock were exchanged, compared to its average volume of 1,760,386. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $530.54. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. The firm has a 50-day moving average price of $360.74 and a 200-day moving average price of $346.48. The stock has a market cap of $46.03 billion, a price-to-earnings ratio of 24.21, a P/E/G ratio of 2.33 and a beta of 0.51.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $9.38 EPS. As a group, equities analysts anticipate that Humana Inc. will post 16.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

HUM has been the topic of several research reports. Morgan Stanley initiated coverage on shares of Humana in a report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 price target on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $360.00 price target on shares of Humana in a report on Wednesday, June 12th. Truist Financial raised their price objective on shares of Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research note on Monday. Wells Fargo & Company dropped their price objective on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research note on Monday, April 8th. Finally, The Goldman Sachs Group dropped their price objective on shares of Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Fourteen investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $402.05.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.